Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. (4th November 2015)

• Record Type: Journal Article
• Authors: Powderly, John; Cote, Gregory; Flaherty, Keith; Szmulewitz, Russell Z; Ribas, Antoni; Weber, Jeffrey; Loo, Deryk; Baughman, Jan; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; Wigginton, Jon; Cohen, Roger; Burris, Howard; Chmielowski, Bartosz
• Is Part Of: Journal for immunotherapy of cancer. Volume 3(2015)Supplement 2
• Publication Date: 2015-11-04
• Subjects: Renal Cell Carcinoma -- Dose Escalation -- Checkpoint Inhibitor -- Expansion Cohort -- Lymphocyte Phenotype; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/2051-1426-3-S2-O8
• Languages: English
• ISSNs: 2051-1426